Nicotinamide Riboside Combo Improves Hepatic Profiles in NAFLD

By August West, Contributing Writer

Supplementation with fixed combination of nicotinamide riboside, L-carnitine, L-serine, and N-acetyl cysteine resulted in improvement of myriad biomarkers of NAFLD (Image: Zeybel M, et al. Mol Syst Biol. 2021)

Daily supplementation with a fixed dose combination of nicotinamide riboside, L-carnitine, L-serine, and N-acetyl cysteine significantly reduced liver fat, quelled oxidative stress, and improved liver enzyme profiles in a cohort of 31 patients with non-alcoholic fatty liver disease (NAFLD).

Defined as hepatic fat accumulation of 5% or more, unrelated to alcohol consumption or other liver diseases, NAFLD affects roughly one in four adults according to recent estimates. Incidence is on the rise, driven in part by the close association of NAFLD with insulin resistance, diabetes, and obesity, all of which are increasing globally.

“Current management strategies, including lifestyle modification, increased physical activity, and dietary intervention, have limited adherence and minimal prolonged success,” wrote Mujdat Zeybel, of the NIHR Nottingham Biomedical Research Center, UK, and lead author of the new study.

[ ...Read More ]

Featured Articles

Himalayan Tartary Buckwheat: Bitter is Better…and Gluten-Free

Written by Sally LaMont, ND, LAc, Contributing Writer

One of the most exciting advances to emerge from the public’s heightened awareness of celiac disease and gluten sensitivity is the rediscovery of ancient, gluten-free, heirloom seeds and grains. Himalayan Tartary Buckwheat (Fagopyrum tataricum) – a naturally gluten-free variety of buckwheat–-is an excellent example of such a rediscovery. This nutrient-rich strain of buckwheat originated in […]

[ ...Read More ]

Uric Acid is Detrimental to Gut Health

Written by Kristen Schepker

“People who suffer from chronic elevated uric acid tend to harbor unhealthy biomes,” says neurologist David Perlmutter, MD. In his latest book, Drop Acid: The Surprising New Science of Uric Acid, Perlmutter presents several studies showing that adverse changes in the gut microbiome directly relate to our ability to metabolize and eliminate uric acid (UA). The intricate interplay between hyperuricemia and the gut microbiome is still a relatively new field of research. But it has already led to some interesting discoveries.

[ ...Read More ]

HPC Video

Improving Clinical Outcomes with Paraprobiotics

Written by Erik Goldman

Paraprobiotics could be just what your patients need for a better life. Pre- and probiotics have become mainstream solutions for improved overall wellbeing, but research has revealed that paraprobiotics–heat-killed probiotic strains–can also have very specific benefits. Paraprobiotics also deliver the added advantage of a longer shelf-life without the need for refrigeration.

In this free webinar, Danielle Citrolo, PharmD, and Shintaro Ichikawa, PhD, will discuss how paraprobiotics will benefit your patients. They will introduce you to IMMUSE and EYEMUSE, two branded forms of clinically studied strains that help to bolster immune function and vision by stimulating immune cells within the gut and the retina. IMMUSE is currently supported by eleven human trials and EYEMUSE is supported by two studies.

In this webinar, you will:

  • Gain an understanding of what are paraprobiotics, and why they could be a good alternative to probiotic strains in your practice.
  • Learn the importance of the immune system and its role in overall health. 
  • Understand the ability of paraprobiotics to influence the immune system for improved health outcomes.
  • Learn about the published clinical research behind the unique paraprobiotic strains used for IMMUSE and EYEMUSE.


Danielle Citrolo, PharmD is a registered pharmacist who provides scientific and regulatory support to Kyowa’s customers in the US, Canada and Latin America. She holds degrees in biochemistry and chemistry from North Carolina State University and a Doctor of Pharmacy from Albany College of Pharmacy, NY.

Shintaro Ichikawa, PhD, is the Director of Technical Affairs at Kyowa Hakko USA. He is leading the launch of IMMUSE™, the company’s unique Lactococcus lactis strain, in the United States. He previously led the launch of IMMUSE™ in Japan. Dr. Ichikawa holds a Doctorate in Life Science from the University of Tokyo, Department of Applied Biochemistry.

[ ...Read More ]

Subscribe to Holistic Primary Care

Learn to Improve Bone and Total Body Health - New Book

Get Premium Web Access